2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. Aurora Kinase

Aurora Kinase

Kinase

Aurora Kinase

Related Products

PDF 0.27 MB

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Aurora Kinase Isoform Specific Products:

Aurora Kinase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12054A
    Hesperadin hydrochloride
    		Inhibitor
    Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of Aurora A and B. Hesperadin hydrochloride inhibits Aurora B with an IC50 of 250 nM.
    Hesperadin hydrochloride
  • HY-111506
    Aurora inhibitor 1
    		Inhibitor
    Aurora inhibitor 1 is a potent Aurora inhibitor with an IC50 of ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase, respectively.
    Aurora inhibitor 1
  • HY-168540
    PROTAC MPS1 degrader 1
    		Degrader
    PROTAC MPS1 degrader 1 (Compound 19) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA and AURKB, with DC50s of 17.7, 108.7 and 570.3 nM, respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168542); Black: linker (HY-W141926); Blue: ligand for E3 ligase (HY-10984).
    PROTAC MPS1 degrader 1
  • HY-149354
    Aurora kinase-IN-4
    		Inhibitor
    Aurora kinase-IN-4 (Compound 11c) is a covalent and ATP competitive aurora kinase A inhibitor (IC50: 1.7 nM). Aurora kinase-IN-4 inhibits cell proliferation in SJSA-1, MDA-MB-231, A54, HeLa cells with IC50s of 4.27, 1.54, 3.08, 6.99 μM. Aurora kinase-IN-4 can be used for research of triple negative breast cancer (TNBC).
    Aurora kinase-IN-4
  • HY-168543
    PROTAC MPS1 degrader 2
    		Degrader
    PROTAC MPS1 degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1，TTK)，AURKA and AURKB，with DC50s of 42.0，2.1 and 154.0 nM，respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168545); Black: linker (HY-N0420); Blue: ligand for E3 ligase (HY-10984).
    PROTAC MPS1 degrader 2
  • HY-137344
    dAURK-4
    		Inhibitor
    dAURK-4, an Alisertib (HY-10971) derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 has anticancer effects.
    dAURK-4
  • HY-155464
    VEGFR-2/AURKA-IN-1
    		Chemical
    VEGFR-2/AURKA-IN-1 (compound 5e) is a thiazolidin-4-one derivative with antiglioma activity (IC50: 6.43 μM, LN229). VEGFR-2/AURKA-IN-1 has affinity for AURKA and VEGFR-2 and is a potential ligand. VEGFR-2/AURKA-IN-1 causes DNA strand breaks and exhibits cytotoxic and anticancer potential.
    VEGFR-2/AURKA-IN-1
  • HY-162469
    6K465
    		Inhibitor
    6K465 is a pyrimidine-based Aurora A (AURKA) inhibitor. 6K465 can reduce the levels of c-MYC and N-MYC oncoproteins, demonstrating anticancer activity.
    6K465
  • HY-161407
    AURKA-IN-1
    		Inhibitor
    AURKA-IN-1 (compound 9) is an cell-active covalent AURKA inhibitor. AURKA-IN-1 is a lysine-reactive activity probe.
    AURKA-IN-1
  • HY-RS01266
    AURKA Human Pre-designed siRNA Set A
    		Inhibitor

    AURKA Human Pre-designed siRNA Set A contains three designed siRNAs for AURKA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKA Human Pre-designed siRNA Set A
    AURKA Human Pre-designed siRNA Set A
  • HY-149694
    Aurora kinase inhibitor-12
    		Inhibitor
    Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth.
    Aurora kinase inhibitor-12
  • HY-115932
    Aurora kinase-IN-1
    		Inhibitor
    Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of aurora kinase. Aurora kinase-IN-1 upregulates the expression of G1 cell cycle inhibitory proteins including p21 and p27, and G1 progressive cyclin D1, and downregulates G1-to-S progressive cyclins, resulting in cell cycle arrest at the G1/S boundary. Aurora kinase-IN-1 also induces apoptosis. Aurora kinase-IN-1 is a lead compound for chemotherapeutic agents.
    Aurora kinase-IN-1
  • HY-125158A
    (E/Z)-HOI-07
    		Inhibitor
    (E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity.
    (E/Z)-HOI-07
  • HY-146037
    Aurora A inhibitor 2
    		Inhibitor
    Aurora A inhibitor 2 (Compound 16h) is a potent Aurora A kinase inhibitor with an IC50 of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent apoptosis in MDA-MB-231 cells.
    Aurora A inhibitor 2
  • HY-N12436
    11α-O-Tigloyl-12β-O-acetyltenacigenin B
    11α-O-Tigloyl-12β-O-acetyltenacigenin B is an ester derivative of Tenacigenin B (HY-N1168), which is isolated from Garcinia cambogia (MTC). Tenacigenin B modulates the antitumor effects of Aurora-A in lymphoma.
    11α-O-Tigloyl-12β-O-acetyltenacigenin B
  • HY-RS01275
    AURKC Rat Pre-designed siRNA Set A
    		Inhibitor

    AURKC Rat Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKC Rat Pre-designed siRNA Set A
    AURKC Rat Pre-designed siRNA Set A
  • HY-160691
    GW814408X
    		Inhibitor
    GW814408X is a kinase chemical genome group (KCGS) compound that inhibits the AURKC kinase involved in cell cycle progression, checkpoint regulation, and cell division. GW814408X exhibits cell line-dependent toxicity, e.g., cytotoxic effects on HeLa cells. GW814408X acts as a protein kinase inhibitor across ATP-dependent and -independent luciferases with potential implications for Fluc reporter assays.
    GW814408X
  • HY-172779
    AURKA-IN-2
    		Inhibitor
    AURKA-IN-2 (Compound 10) is an inhibitor of AURKA. By inhibiting the protein expression of AURKA and its interaction with N-Myc, it significantly suppresses the proliferation and migration of SK-N-BE cells and induces Apoptosis. AURKA-IN-2 can remarkably inhibit tumor growth in a mouse neuroblastoma model, exerting potential anti-neuroblastoma activity, and it can be used in the research of neuroblastoma.
    AURKA-IN-2
  • HY-RS01273
    AURKC Human Pre-designed siRNA Set A
    		Inhibitor

    AURKC Human Pre-designed siRNA Set A contains three designed siRNAs for AURKC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    AURKC Human Pre-designed siRNA Set A
    AURKC Human Pre-designed siRNA Set A
  • HY-162837
    AURKA against 1
    		Inhibitor
    AURKA against 1 is an inhibitor of AURKA (IC50 less than 0.5 nM), targeting endogenous lysine (K162) acetylation, and has anti-proliferation activity against tumor cells. AURKA against 1 induces K162 acetylation, and the kinase activity of AURKA is reversibly restored in HCT116 cells transfected with SIRT3.
    AURKA against 1
Cat. No. Product Name / Synonyms Application Reactivity
Aurora Kinase Isoform Comparison

Aurora Kinase

Aurora A

Aurora B

Aurora C

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Aurora Kinase Degraders & Inhibitors
Product NameAurora KinaseAurora AAurora BAurora CPurity    
Alisertib 
Aurora A, IC50: 1.2 nM
Aurora B, IC50: 396.5 nM
 99.84%
Barasertib-HQPA  
Aurora B, IC50: 0.37 nM
 99.47%
Barasertib  
Aurora B, IC50: 0.37 nM
 99.62%
Reversine 
Aurora A, IC50: 400 nM
Aurora B, IC50: 500 nM
Aurora C, IC50: 400 nM
99.22%
Tozasertib 
Aurora A, Ki: 0.6 nM
Aurora B, Ki: 18 nM
Aurora C, Ki: 4.6 nM
99.92%
Aurora kinase inhibitor-13 
Aurora A, IC50: 2.3 μM
  
FAK-IN-22  
Aurora B, IC50: 0.49 nM
 
JNJ-7706621 
Aurora A, IC50: 11 nM
Aurora B, IC50: 15 nM
 99.91%
Hesperadin  
Aurora B, IC50: 250 nM
 98.89%
AT9283 
Aurora A, IC50: 3 nM
Aurora B, IC50: 3 nM
 99.67%
KW-2449 
Aurora A, IC50: 48 nM
  99.91%
MK-5108 
Aurora A, IC50: 64 pM
  99.89%
AMG 900 
Aurora A, IC50: 5 nM
Aurora B, IC50: 4 nM
Aurora C, IC50: 1 nM
99.05%
ZM-447439 
Aurora A, IC50: 110 nM
Aurora B, IC50: 130 nM
 99.19%
GSK-1070916  
Aurora B, Ki: 0.38 nM
Aurora C, Ki: 1.5 nM
99.55%
LY3295668 
Aurora A, IC50: 0.8 nM
  99.48%
Danusertib 
Aurora A, IC50: 13 nM
Aurora B, IC50: 79 nM
Aurora C, IC50: 61 nM
99.44%
PF 477736 
Aurora-A, IC50: 23 nM
  99.21%
MLN8054 
Aurora A, IC50: 4 nM
  99.54%
PF-03814735 
Aurora 1, IC50: 0.8 nM
Aurora 2, IC50: 5 nM
 99.58%
TAK-632  
Aurora B, IC50: 66 nM
 98.84%
GRK6-IN-1 
Aurora A, IC50: 8.9 μM
  99.61%
SNS-314 mesylate 
Aurora A, IC50: 9 nM
Aurora B, IC50: 31 nM
Aurora C, IC50: 6 nM
99.53%
JB170 
Aurora A, DC50: 28 nM
Aurora A, Kd: 99 nM
Aurora A, EC50: 193 nM
  98.97%
ENMD-2076 
Aurora A, IC50: 14 nM
  99.99%
Ilorasertib hydrochloride 
Aurora A, IC50: 120 nM
Aurora B, IC50: 7 nM
Aurora B (Y156H), IC50: 12 nM
Aurora C, IC50: 1 nM
98.48%
XL228 
Aurora A, IC50: 3.1 nM
  99.64%
Cenisertib 
Aurora-A
Aurora-B
 99.86%
Tinengotinib 
Aurora A
Aurora B
 98.45%
TCS7010 
Aurora A, IC50: 3.4 nM
Aurora B, IC50: 3.4 μM
 99.82%
SP-96 
Aurora A, IC50: 18.975 nM
Aurora B, IC50: 0.316 nM
 99.42%
CCT129202 
Aurora A, IC50: 42 nM
Aurora B, IC50: 198 nM
Aurora C, IC50: 227 nM
≥98.0%
BI-847325   
Aurora C, IC50: 15 nM
98.15%
TAK-901 
Aurora A, IC50: 21 nM
Aurora B, IC50: 15 nM
 99.84%
CCT 137690 
Aurora A, IC50: 15 nM
Aurora B, IC50: 25 nM
Aurora C, IC50: 19 nM
99.54%
GRK2 Inhibitor 2 
Aurora A, IC50: 137 nM
  98.88%
SCH-1473759 hydrochloride 
Aurora A, IC50: 4 nM
Aurora B, IC50: 13 nM
 99.79%
CYC-116 
Aurora A, Ki: 8 nM
Aurora B, Ki: 9.2 nM
 99.03%
CD532 
Aurora A, IC50: 45 nM
  98.78%
GW779439X 
Aurora A
  99.85%
NU6140 
Aurora A, IC50: 67 nM
Aurora B, IC50: 35 nM
 99.07%
Chiauranib  
Aurora B, IC50: 9 nM
 99.28%
MK-8745 
Aurora A, IC50: 0.6 nM
  99.08%
TAS-119 
Aurora A, IC50: 1 nM
Aurora B, IC50: 95 nM
 98.03%
DB0614
Aurora Kinase
   98.80%
PHA-680632 
Aurora A, IC50: 27 nM
Aurora B, IC50: 135 nM
Aurora C, IC50: 120 nM
98.07%
Aurora kinase inhibitor-3 
Aurora A, IC50: 42 nM
  99.05%
Aurkin A 
Aurora A, Kd: 3.77 μM
  ≥98.0%
dAURK-4 hydrochloride 
Aurora A
  99.44%
Ilorasertib 
Aurora A, IC50: 120 nM
Aurora B, IC50: 7 nM
Aurora B (Y156H), IC50: 12 nM
Aurora C, IC50: 1 nM
99.86%
GSK2646264 
Aurora A, pIC50: <4.3
Aurora B, pIC50: <4.6
 98.39%
ENMD-2076 Tartrate 
Aurora A, IC50: 1.86 nM
  99.42%
SCH-1473759 
Aurora A, IC50: 4 nM
Aurora B, IC50: 13 nM
 98.20%
AKI603 
Aurora A, IC50: 12.3 nM
  98.03%
Aurora kinase inhibitor-2 
Aurora A, IC50: 310 nM
Aurora B, IC50: 240 nM
 99.08%
CCT241736 
Aurora-A, IC50: 38 nM
Aurora-A, Kd: 7.5 nM
Aurora-B, Kd: 48 nM
 99.88%
TC-A 2317 hydrochloride 
Aurora A, Ki: 1.2 nM
Aurora B, Ki: 101 nM
 99.57%
Phthalazinone pyrazole 
Aurora-A, IC50: 0.031 μM
  ≥98.0%
AurkA allosteric-IN-1 
Aurora A, IC50: 6.5 μM ([1])
  
Alisertib sodium 
Aurora A, IC50: 12.5 nM
Aurora B, IC50: 396.5 nM
 
AT9283 lactic acid 
Aurora A, IC50: 3 nM
Aurora B, IC50: 3 nM
 
Hesperadin hydrochloride  
Aurora B, IC50: 250 nM
 
Aurora inhibitor 1 
Aurora A, IC50: 4 nM
Aurora B, IC50: 13 nM
 
PROTAC MPS1 degrader 1 
Aurora A, DC50: 108.7 nM
Aurora B, DC50: 570.3 nM
 
dAURK-4 
Aurora A
  
Aurora A inhibitor 2 
Aurora A, IC50: 21.94 nM
Aurora B, IC50: 273.18 nM
 
AURKA-IN-2 
Aurora A
  
RET-IN-19 
Aurora A, IC50: 0.242 ± 0. μM
Aurora B, IC50: 0.536 ± 45 μM
 
SNS-314 
Aurora A, IC50: 9 nM
Aurora B, IC50: 31 nM
Aurora C, IC50: 6 nM
Aurora kinase inhibitor-10  
Aurora B, IC50: 8 nM
 
Glycyl H-1152 hydrochloride 
Aurora A, IC50: 2.35 μM
  
Aurora A/PKC-IN-1 
Aurora A, IC50: 6.9 nM
  
Aurora kinase-IN-5 
Aurora A, IC50: 5.6 nM
Aurora B, IC50: 18.4 nM
Aurora C, IC50: 24.6 nM
Aurora kinase-IN-2 
Aurora A, IC50: 90 nM
Aurora B, IC50: 152 nM
 
Aurora kinase inhibitor-9 
Aurora A, IC50: 0.093 μM
Aurora B, IC50: 0.09 μM
 
BRD-7880 
Aurora A, IC50: 2153 nM
Aurora B, IC50: 7 nM
Aurora C, IC50: 12 nM
SAR156497 
Aurora A, IC50: 0.6 nM
Aurora B, IC50: 1 nM
 
TAK-901 hydrochloride 
Aurora A, IC50: 21 nM
Aurora B, IC50: 15 nM
 
(Rac)-Aurora A/PKC-IN-1 
Aurora A, IC50: 6.9 nM
  
Benzo[c][1,8]naphthyridin-6(5H)-one 
Aurora A, IC50: 5.5 μM
  
TY-011 
Aurora A
Aurora B
 
Binucleine 2  
Aurora B
 
Aurora A inhibitor 4 
Aurora A
  
Aurora B inhibitor 1  
Aurora B, Ki: 0.01 μM